Targeting the TGF-β signaling pathway for fibrosis therapy: a patent review (2015-2020).
Xuanyi LiZiang DingZixuan WuYinqiu XuHequan YaoKejiang LinPublished in: Expert opinion on therapeutic patents (2021)
Since the approval of pirfenidone, targeting TGF-β signaling has been anticipated as an effective therapy for fibrosis. The potential of this therapy has been further supported by emerging patents on the TGF-β signaling. This pathway can be entirely inhibited, from the activation of TGF-β to downstream signaling. Inhibiting TGF-β signaling is expected to provide more effective treatments for fibrosis.